236 related articles for article (PubMed ID: 27400983)
1. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
Langballe R; Mellemkjær L; Malone KE; Lynch CF; John EM; Knight JA; Bernstein L; Brooks J; Andersson M; Reiner AS; Liang X; Woods M; Concannon PJ; ; Bernstein JL
Breast Cancer Res; 2016 Jul; 18(1):65. PubMed ID: 27400983
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
3. Reproductive history and risk of second primary breast cancer: the WECARE study.
Largent JA; Capanu M; Bernstein L; Langholz B; Mellemkaer L; Malone KE; Begg CB; Haile RW; Lynch CF; Anton-Culver H; Wolitzer A; Bernstein JL
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):906-11. PubMed ID: 17507614
[TBL] [Abstract][Full Text] [Related]
4. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
6. Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study.
Knight JA; Fan J; Malone KE; John EM; Lynch CF; Langballe R; Bernstein L; Shore RE; Brooks JD; Reiner AS; Woods M; Liang X; Bernstein JL;
Int J Cancer; 2017 Sep; 141(5):916-924. PubMed ID: 28524234
[TBL] [Abstract][Full Text] [Related]
7. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
[TBL] [Abstract][Full Text] [Related]
8. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
[TBL] [Abstract][Full Text] [Related]
9. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
Knight JA; Blackmore KM; Fan J; Malone KE; John EM; Lynch CF; Vachon CM; Bernstein L; Brooks JD; Reiner AS; Liang X; Woods M; ; Bernstein JL
Breast Cancer Res; 2018 Mar; 20(1):23. PubMed ID: 29566728
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Brooks JD; Comen EA; Reiner AS; Orlow I; Leong SF; Liang X; Mellemkjær L; Knight JA; Lynch CF; John EM; Bernstein L; Woods M; Doody DR; ; Malone KE; Bernstein JL
Breast Cancer Res; 2018 Dec; 20(1):149. PubMed ID: 30526633
[TBL] [Abstract][Full Text] [Related]
11. Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study.
Robson ME; Reiner AS; Brooks JD; Concannon PJ; John EM; Mellemkjaer L; Bernstein L; Malone KE; Knight JA; Lynch CF; Woods M; Liang X; Haile RW; Duggan DJ; Shore RE; Smith SA; Thomas DC; Stram DO; Bernstein JL;
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521362
[TBL] [Abstract][Full Text] [Related]
12. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.
Gao X; Fisher SG; Emami B
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1038-45. PubMed ID: 12829139
[TBL] [Abstract][Full Text] [Related]
13. Body mass index and risk of second primary breast cancer: the WECARE Study.
Brooks JD; John EM; Mellemkjær L; Reiner AS; Malone KE; Lynch CF; Figueiredo JC; Haile RW; Shore RE; ; Bernstein JL; Bernstein L
Breast Cancer Res Treat; 2012 Jan; 131(2):571-80. PubMed ID: 21892703
[TBL] [Abstract][Full Text] [Related]
14. Risk of contralateral breast cancer after tamoxifen use among Danish women.
Mellemkjær L; Steding-Jessen M; Frederiksen K; Andersson M; Ejlertsen B; Jensen MB; Olsen JH
Ann Epidemiol; 2014 Nov; 24(11):843-8. PubMed ID: 25277504
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for contralateral breast cancer in Chennai (Madras), India.
Gajalakshmi CK; Shanta V; Hakama M
Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
[TBL] [Abstract][Full Text] [Related]
16. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
[TBL] [Abstract][Full Text] [Related]
17. A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study.
Brooks JD; Boice JD; Shore RE; Reiner AS; Smith SA; Bernstein L; Knight JA; Lynch CF; John EM; Malone KE; Mellemkjaer L; Langballe R; Liang X; Woods M; Tischkowitz M; Concannon P; Stram DO;
Breast; 2020 Dec; 54():62-69. PubMed ID: 32927238
[TBL] [Abstract][Full Text] [Related]
18. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
[TBL] [Abstract][Full Text] [Related]
20. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group.
Figueiredo JC; Bernstein L; Capanu M; Malone KE; Lynch CF; Anton-Culver H; Stovall M; Bertelsen L; Haile RW; Bernstein JL;
J Clin Oncol; 2008 Mar; 26(9):1411-8. PubMed ID: 18250348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
